AKTX

NASDAQ HEALTHCARE

Akari Therapeutics PLC

$10.99

$0.11 (+1.01%)

Live quote

52w: $3.02 – $49.60

Loading chart…

P/E Ratio—

P/B Ratio91134.87

EV/EBITDA—

Debt/Equity—

ROE-93.03%

ROIC—

Revenue Growth-39.46%

Gross Margin—

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom.

Own AKTX? Track it here.

Create a free account to add AKTX to a portfolio and watch your P/L update in real time.

Custom screens, valuation models and backtesting are coming to Pro.

Create a free account